Once-daily oral icotrokinra produced sustained plaque psoriasis control through week 112, including scalp, genital, ...
Patient-reported burden improved in adults, with DLQI dropping from 14.5 to 7.9 and itch/pain numerical rating scales ...
Yassky, MD, PhD, explains how biomarkers could match patients with inflammatory skin diseases to the right therapy. Emma ...
The National Eczema Association (NEA) has released the State of AD 2026 National Indicator Report, a Milliman analysis ...
Two global randomized phase 3 studies evaluated ritlecitinib 100 mg (n=1567; exploratory 50 mg) and 50 mg (n=607; age ≥12), ...
New data presented at the 2026 European Academy of Dermatology and Venereology (EADV) Congress highlight the effects of ...
Nearly 95% of assessed TikTok “glass skin” videos contained potentially misleading claims, with none citing external references and none produced by dermatologists.
Day 2 of EADV 2026 highlighted new findings involving GLP-1–associated nail changes, long-term atopic dermatitis control, emerging therapies, alopecia, and hidradenitis suppurativa. The second day of ...
Phase 3 ABTECT-Maintenance will report 44-week efficacy and safety of obefazimod in moderately to severely active UC using a randomized, double-blind, placebo-controlled design. Subset analyses will ...
Intralesional BO-112 demonstrated promising clinical and pathological responses in patients with resectable basal cell ...
ILT7 is selectively expressed on plasmacytoid dendritic cells, and daxdilimab binding is intended to reduce pDCs in tissue ...
Explore the top headlines of the month, including insights on the latest clinical trials, therapeutic updates, and more.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results